Abstract
Greater understanding of the underlying pathophysiology of acute myocardial infarction (AMI) has led to more aggressive management and lower mortality, both in-hospital and long term. AMI results mainly from thrombotic occlusion of the infarct-related coronary artery. The ensuing necrosis evolves over a 6-12 h period providing a time window for interventions designed to reduce eventual infarct size. The most appropriate interventions are those which restore coronary artery patency and hence myocardial blood flow as soon as possible. Occasionally, disruption of the occluding thrombus and compression of the underlying atheromatous lesion is best achieved by direct percutaneous transluminal coronary angioplasty. For the vast majority however, revascularisation by drug therapy is more appropriate. As soon as possible, all patients without contraindications should be offered oral aspirin and intravenous thrombolysis, usually with streptokinase but occasionally with tissue plasminogen activator. Patients in whom these agents are contraindicated should be considered for intravenous beta-blockade using atenolol or metoprolol to reduce myocardial demand and hence infarct size. Patients with large infarcts, impaired ventricular function, left ventricular failure or hypertension should be considered for early angiotensin-converting enzyme inhibitor therapy. Other agents may be valuable symptomatically, but have no proven role in reducing infarct size or mortality. After the first 24 h, the main aims of management are to assess the likelihood of later ischaemic events or death (risk stratification) and hence to choose appropriate long term secondary prophylaxis.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Anderson H. V., Willerson J. T. Thrombolysis in acute myocardial infarction. N Engl J Med. 1993 Sep 2;329(10):703–709. doi: 10.1056/NEJM199309023291006. [DOI] [PubMed] [Google Scholar]
- De Bono D. P., Hopkins A. The management of acute myocardial infarction: guidelines and audit standards. Report of a workshop of the Joint Audit Committee of the British Cardiac Society and the Royal College of Physicians. J R Coll Physicians Lond. 1994 Jul-Aug;28(4):312–317. [PMC free article] [PubMed] [Google Scholar]
- Grech E. D., Ramsdale D. R. Percutaneous transluminal coronary angioplasty and acute myocardial infarction. 1994 Jun 15-Jul 12Br J Hosp Med. 52(1):35–41. [PubMed] [Google Scholar]
- Grines C. L., Browne K. F., Marco J., Rothbaum D., Stone G. W., O'Keefe J., Overlie P., Donohue B., Chelliah N., Timmis G. C. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med. 1993 Mar 11;328(10):673–679. doi: 10.1056/NEJM199303113281001. [DOI] [PubMed] [Google Scholar]
- Landau C., Lange R. A., Hillis L. D. Percutaneous transluminal coronary angioplasty. N Engl J Med. 1994 Apr 7;330(14):981–993. doi: 10.1056/NEJM199404073301407. [DOI] [PubMed] [Google Scholar]
- Lown B., Wolf M. Approaches to sudden death from coronary heart disease. Circulation. 1971 Jul;44(1):130–142. doi: 10.1161/01.cir.44.1.130. [DOI] [PubMed] [Google Scholar]
- MacMahon S., Collins R., Peto R., Koster R. W., Yusuf S. Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. JAMA. 1988 Oct 7;260(13):1910–1916. [PubMed] [Google Scholar]
- McMurray J., Rankin A. Cardiology--I: Treatment of myocardial infarction, unstable angina, and angina pectoris. BMJ. 1994 Nov 19;309(6965):1343–1350. doi: 10.1136/bmj.309.6965.1343. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Swedberg K., Held P., Kjekshus J., Rasmussen K., Rydén L., Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) N Engl J Med. 1992 Sep 3;327(10):678–684. doi: 10.1056/NEJM199209033271002. [DOI] [PubMed] [Google Scholar]
- Teo K. K., Yusuf S., Collins R., Held P. H., Peto R. Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. BMJ. 1991 Dec 14;303(6816):1499–1503. doi: 10.1136/bmj.303.6816.1499. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Turpie A. G., Robinson J. G., Doyle D. J., Mulji A. S., Mishkel G. J., Sealey B. J., Cairns J. A., Skingley L., Hirsh J., Gent M. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med. 1989 Feb 9;320(6):352–357. doi: 10.1056/NEJM198902093200604. [DOI] [PubMed] [Google Scholar]
- Weston C. F., Penny W. J., Julian D. G. Guidelines for the early management of patients with myocardial infarction. British Heart Foundation Working Group. BMJ. 1994 Mar 19;308(6931):767–771. doi: 10.1136/bmj.308.6931.767. [DOI] [PMC free article] [PubMed] [Google Scholar]
- de Bono D. Coronary thrombolysis. Br Heart J. 1987 Apr;57(4):301–305. doi: 10.1136/hrt.57.4.301. [DOI] [PMC free article] [PubMed] [Google Scholar]